Kontafarma China Holdings (HKG:1312) expects a consolidated net loss between HK$79.2 million and HK$118.8 million in 2024, wider than the HK$61.1 million net loss in 2023, a Tuesday Hong Kong bourse filing said.
The pharmaceutical company attributed the anticipated increase to an impairment recognized on intangible assets associated with its fitness business, as well as the absence of a one-time gain from the disposal of subsidiaries, which had been recorded during the same period last year.
Shares of the company were down nearly 7% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。